Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

• Market Cap: ₹122.70B
• Dividend Yield: 0.14%
• Average Volume (3M): 66.70K
• Price to Earnings (P/E): 34.2
• Beta (1Y): 0.62
• Revenue Growth: 75.82%
• EPS Growth: 127.85%
• Country: IN
• Employees: 447
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 5.30
• Shares Outstanding: 173,465,420
• 10 Day Avg. Volume: 22,190
• 30 Day Avg. Volume: 66,703
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹909.00
• Price Target Upside: 32.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 68 Neutral
• Price Target: ₹888.00 ▲(29.27% Upside)

Blue Jet Healthcare's stock score reflects strong financial performance driven by significant revenue growth and profitability. However, technical indicators signal bearish momentum, and valuation metrics suggest potential overvaluation. The absence of earnings call and corporate events data means these factors did not impact the score.

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company Description

Blue Jet Healthcare Limited (BLUEJET) is a pharmaceutical company that operates in the healthcare sector. It specializes in the development, production, and marketing of specialty pharmaceutical products. The company's core offerings include active pharmaceutical ingredients (APIs) and intermediates, with a focus on niche segments within the pharmaceutical industry.

How the Company Makes Money

Blue Jet Healthcare Limited makes money primarily through the sale of its active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. These products are used in the formulation of a variety of medications, allowing Blue Jet to tap into the global pharmaceutical supply chain. The company's revenue streams are bolstered by long-term contracts with major pharmaceutical companies, ensuring a steady demand for its products. Additionally, Blue Jet may engage in strategic partnerships and collaborations to expand its market presence and enhance its product offerings, contributing to its overall earnings.

Blue Jet Healthcare Limited Financial Statement Overview

Summary

Blue Jet Healthcare shows strong financial performance with robust revenue growth of 45.01% and high profitability margins. The balance sheet is stable with minimal leverage and high equity ratio. However, challenges in free cash flow generation present a concern.

Income Statement

Blue Jet Healthcare has demonstrated strong financial performance with significant growth in total revenue from ₹7,103 million in 2024 to ₹10,299 million in 2025, reflecting a robust revenue growth rate of 45.01%. The gross profit margin improved to 55.24% in 2025, indicating efficient cost management. The net profit margin also increased to 29.65%, reflecting higher profitability. EBIT and EBITDA margins are solid at 49.30% and 41.18%, respectively. Overall, the income statement shows excellent growth and profitability.

Balance Sheet

The balance sheet of Blue Jet Healthcare reveals strong financial health with a low debt-to-equity ratio of 0.02, indicating minimal leverage. The equity ratio stands at 79.94%, showcasing a high level of financial stability. Return on equity (ROE) is impressive at 26.93%, reflecting effective use of equity to generate profits. The company's significant equity base and low debt level highlight its stability and low risk.

Cash Flow

Blue Jet Healthcare's cash flow performance is mixed. The operating cash flow to net income ratio is 0.15, suggesting lower cash conversion efficiency. However, the free cash flow to net income ratio is negative due to the decrease in free cash flow from ₹669 million in 2024 to -₹341 million in 2025, indicating challenges in generating free cash flow. While the company maintains positive operating cash flow, the pressure on free cash flow presents a potential area of concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.30B	10.30B	7.10B	7.18B	6.77B	4.94B
Gross Profit	5.30B	5.69B	3.89B	2.70B	2.97B	2.47B
EBITDA	4.11B	4.24B	2.48B	2.43B	2.69B	2.15B
Net Income	3.05B	3.05B	1.64B	1.60B	1.82B	1.38B
Balance Sheet
Total Assets	14.18B	14.18B	10.59B	8.62B	7.13B	5.36B
Cash, Cash Equivalents and Short-Term Investments	3.06B	3.06B	3.09B	2.55B	1.81B	979.70M
Total Debt	199.86M	199.86M	16.13M	34.40M	173.17M	516.15M
Total Liabilities	2.84B	2.84B	2.14B	1.81B	1.92B	1.96B
Stockholders Equity	11.33B	11.33B	8.45B	6.81B	5.22B	3.40B
Cash Flow
Free Cash Flow	0.00	-341.15M	669.59M	822.79M	1.21B	807.67M
Operating Cash Flow	0.00	457.65M	2.41B	1.42B	1.44B	1.30B
Investing Cash Flow	0.00	-351.83M	-2.64B	-1.47B	-760.26M	-566.48M
Financing Cash Flow	0.00	-185.57M	-19.86M	-42.33M	-561.45M	-221.90M

Blue Jet Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 686.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 686.95 is below the 20-day moving average (MA) of 774.48, below the 50-day MA of 841.31, and below the 200-day MA of 741.18, indicating a bearish trend. The MACD of -34.03 indicates Positive momentum. The RSI at 26.27 is Positive, neither overbought nor oversold. The STOCH value of 2.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	68 Neutral	₹253.83B	51.33		0.20%	7.41%	2.88%
BLUEJET	68 Neutral	₹122.70B	34.21		0.14%	75.82%	127.85%
CONCORDBIO	67 Neutral	₹178.37B	50.09		0.51%	14.49%	13.70%
SUPRIYA	67 Neutral	₹52.75B	29.58		0.12%	13.68%	31.87%
JUBLINGREA	63 Neutral	₹116.28B	41.50		0.69%	2.60%	60.61%
BIOCON	61 Neutral	₹471.19B	111.88		0.14%	6.80%	-75.66%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%

Blue Jet Healthcare Limited Corporate Events

Blue Jet Healthcare Expands Manufacturing Capacity with New Land Acquisition

Blue Jet Healthcare Limited has announced the acquisition of a 102.48-acre industrial land parcel in Andhra Pradesh, as part of its strategy to expand manufacturing capacity. This move aligns with the company’s long-term growth objectives and is expected to enhance its production capabilities across key therapeutic platforms, potentially strengthening its market position.

Blue Jet Healthcare Releases Q1 FY’26 Earnings Call Transcript

Blue Jet Healthcare Limited has released the transcript of its earnings call for the quarter ended June 30, 2025. The call, held on July 22, 2025, discussed the company’s financial results and was attended by key management figures including the Managing Director and Chief Financial Officer. This release is part of the company’s compliance with SEBI regulations and provides stakeholders with insights into its financial performance.